WILMINGTON,Boosted by revenues which climbed to $70.8 million, aaiPharma reported earnings of 28 cents per share for the second quarter.

Income increased 15 percent over the same quarter in 2002, with pharmaceutical product sales climbing to $45.8 million.

“Our positive second quarter financial performance was driven by strong revenue growth in our pharmaceutical products division,” said Philip Tabbiner, the company’s president and chief executive officer, in a statement. “We are very pleased with the strategic and operational milestones we achieved in the first six months
of 2003 which reflect our continued focus on our core strategy of being ascience-based, specialty pharmaceutical company.”

Revenues totaled $134.8 million for the first six months of this year, an increase of 26 percent over the same time period a year ago. AaiPharma also paid down $8.5 million in debt in each of the first two quarters this year.

aaiPharma: www.aaipharma.com